Sara Karlovitch

A phase 2 study has begun recruiting patients with relapsed/refractory acute myeloid leukemia to test the efficacy of magrolimab.

In a population of patients with chronic myeloid leukemia with resistant disease experienced promising activity following treatment with ponatinib regardless of T315I mutation status.

Utilizing neratinib or abo-trastuzumab emtansine for patients with HER2-positive early stage breast cancer reduced the risk of distant recurrence.

Despite the importance of incorporating palliative care into strategies for metastatic kidney cancer, little data exists in the space, highlighting a need for further research.

Patients with EGFR-mutant non–small cell lung cancer did not experience additional progression-free survival benefit after being treated with osimertinib and bevacizumab.

Patients with intermediate- and poor-risk metastatic renal cell carcinoma experienced promising responses after being treated with perioperative cabozantinib.

Patients with platinum-sensitive recurrent ovarian cancer treated with niraparib had an acceptable safety profile regardless of the dose being adjusted for weight.

A promising objective response rate and a tolerable safety profile were observed with telisotuzumab vedotin monotherapy to treat patients with previously treated c-Met–positive advanced non–small cell lung cancer.